Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (1067)	11/30/2000 3:53:02 PM
From: Dan Spillane	Read Replies (1) \| Respond to of 1298

But looking at the cash, plus the investment in Abgenix, plus the prospects of CEGE itself and CEGE looks compelling--better than cash in many ways. Worth several times the current price. People are incorrectly comparing biotechs to ".coms". The failed ".coms" lived for a few months, had a high burn rate, and no barriers to entry. Biotechs on the other hand have been around for years, just now coming up with profitable products involving years of accumulated research and thus high barriers--perhaps the highest. Invalid comparison, biotechs to .coms ... hasn't CEGE been around for ten years or so!???!? The ones I like are CEGE, RSTA, HGSI, and IMNX.

To: tom pope who wrote (1067)	11/30/2000 3:53:35 PM
From: Bosco	Respond to of 1298

Hi tom - thx for the clarification. I don't know CEGE tax credit situation, but at this point, I don't mind her holding 10% ABGX. Having too much cash sitting in the MM acct is probably not the best use of capital. OTOH, cash is king, having a bundle should help her to gain more IP via acquisitions etc. Of course, this is based on the assumption, which has been correct thus far, CEGE business model has incurred such a low burn rate. If I am not so leveraged, I would like to add position best, Bosco